Nebenwirkungen der Sklerosierungstherapie

Die Schaumsklerosierungstherapie ist eine effiziente, sichere und häufig angewandte Therapiemethode für variköse Venen. In Deutschland ist hierzu nur Polidocanol als Sklerosierungsmittel zugelassen. Nebenwirkungen können, wie bei jeder Therapie, auftreten und reichen von postinflammatorischer Hyperpigmentierung bis zur tiefen Beinvenenthrombose, wobei die schwerwiegenden Nebenwirkungen selten sind. Dieser Artikel soll die Nebenwirkungen genauer darstellen und praktische Tipps für Neuanfänger in der Sklerotherapie geben.

Abstract

Foam sclerotherapy is an efficient and safe therapy for varicose veins. Only Polidocanol is used as a sclerosing agent in Germany. Sclerotherapy can be applied to every form of varicose vein with adjusted concentrations of sclerosing agent. Side effects may occur, as with any form of therapy, and range from postinflammatory hyperpigmentation to deep vein thrombosis, but in general serious side effects are rare. This article aims to further illustrate the side effects and to provide practical advice for sclerotherapy beginners.

Schlüsselwörter

Schaumsklerosierungstherapie - Nebenwirkungen - chronisch venöse Insuffizienz

Keywords

foam sclerotherapy - side effects - chronic venous insufficiency

Publication History

Article published online:
22 February 2024

• Literatur

• 1 Rabe E, Breu FX, Cavezzi A. et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2014; 29 DOI: 10.1177/0268355513483280. (PMID: 23559590)
• 2 Connor DE, Cooley-Andrade O, Goh WX. et al. Detergent sclerosants are deactivated and consumed by circulating blood cells. European Journal of Vascular and Endovascular Surgery 2015; 49 DOI: 10.1016/j.ejvs.2014.12.029. (PMID: 25686663)
• 3 Rathbun S, Norris A, Stoner J. Efficacy and safety of endovenous foam sclerotherapy: Meta-analysis for treatment of venous disorders. Phlebology 2012; 27 DOI: 10.1258/phleb.2011.011111. (PMID: 22349606)
• 4 Rabe E, Breu FX, Flessenkämper I. et al. S2k-Leitlinie Sklerosierungsbehandlung der Varikose. 2018
• 5 Reich-Schupke S, Weyer K, Altmeyer P. et al. Treatment of varicose tributaries with sclerotherapy with polidocanol 0.5 % foam. Vasa – Journal of Vascular Diseases 2010; 39 DOI: 10.1024/0301-1526/a000023.
• 6 Guex JJ, Allaert FA, Gillet JL. et al. Immediate and midterm complications of sclerotherapy: Report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatologic Surgery 2005; 31 DOI: 10.1097/00042728-200502000-00001. (PMID: 15762201)
• 7 Georgiev M. Postsclerotherapy hyperpigmentations: A one-year follow-up. Journal of Dermatologic Surgery and Oncology 1990; 16 DOI: 10.1111/j.1524-4725.1990.tb00088.x. (PMID: 2362024)
• 8 Goldman MP, Sadick NS, Weiss RA. Cutaneous Necrosis, Telangiectatic Matting, and Hyperpigmentation following Sclerotherapy Etiology, Prevention, and Treatment. Dermatologic Surgery 1995; 21 DOI: 10.1111/j.1524-4725.1995.tb00107.x. (PMID: 7600016)
• 9 Gillet JL, Guedes JM, Guex JJ. et al. Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: A controlled multicentre prospective study including 1025 patients. Phlebology 2009; 24 DOI: 10.1258/phleb.2008.008063.
• 10 Rasmussen LH, Lawaetz M, Bjoern L. et al. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. British Journal of Surgery 2011; 98 DOI: 10.1002/bjs.7555. (PMID: 21725957)
• 11 Bihari I, Magyar É. Reasons for ulceration after injection treatment of telangiectasia. Dermatologic Surgery 2001; 27 DOI: 10.1046/j.1524-4725.2001.00298.x.
• 12 Bergan JJ, Weiss RA, Goldman MP. Extensive tissue necrosis following high-concentration sclerotherapy for varicose veins. Dermatologic Surgery 2000; 26 DOI: 10.1046/j.1524-4725.2000.00033.x. (PMID: 10848933)
• 13 Jia X, Mowatt G, Burr JM. et al. Systematic review of foam sclerotherapy for varicose veins. British Journal of Surgery 2007; 94 DOI: 10.1002/bjs.5891. (PMID: 17636511)
• 14 Sarvananthan T, Shepherd AC, Willenberg T. et al. Neurological complications of sclerotherapy for varicose veins. J Vasc Surg 2012; 55 DOI: 10.1016/j.jvs.2011.05.093. (PMID: 21840152)
• 15 Künzlberger B, Pieck C, Altmeyer P. et al. Migraine ophthalmique with reversible scotomas after sclerotherapy with liquid 1% polidocanol. Dermatologic Surgery 2006; 32 DOI: 10.1111/j.1524-4725.2006.32314.x.
• 16 Pradalier A, Vincent D, Hentschel V. et al. Allergie aux sclérosants des varices. Rev Fr Allergol Immunol Clin 1995; 35 DOI: 10.1016/S0335-7457(05)80528-3.
• 17 Feied CF, Jackson JJ, Bren TS. et al. Allergic Reactions to Polidocanol for Vein Sclerosis. J Dermatol Surg Oncol 1992; 20 DOI: 10.1111/j.1524-4725.1992.tb03218.x. (PMID: 8034842)
• 18 Harzheim M, Becher H, Klockgether T. Brain infarct from a paradoxical embolism following a varices operation. Dtsch Med Wochenschr 2000; 125 DOI: 10.1055/s-2007-1024520. (PMID: 10916495)
• 19 Caggiati A, Franceschini M. Stroke following endovenous laser treatment of varicose veins. J Vasc Surg 2010; 51 DOI: 10.1016/j.jvs.2009.07.092. (PMID: 19782516)
• 20 Ma RWL, Pilotelle A, Paraskevas P. et al. Three cases of stroke following peripheral venous interventions. Phlebology 2011; 26 DOI: 10.1258/phleb.2010.010044. (PMID: 21422195)
• 21 Gillet JL. Neurological complications of foam sclerotherapy: Fears and reality. Phlebology 2011; 26 DOI: 10.1258/phleb.2011.011e04. (PMID: 21983656)
• 22 Heller SL, Meyer JR, Russell EJ. Spinal cord venous infarction following endoscopic sclerotherapy for esophageal varices. Neurology 1996; 47 DOI: 10.1212/WNL.47.4.1081. (PMID: 8857750)
• 23 Frings N, Brenner E, Prinz N. et al. Paraplegia following sclerotherapy of leg veins. Phlebologie 2017; 46: 92-97 DOI: 10.12687/phleb2341-2-.